US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Stoke Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
News headline image
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers STOK
News headline image
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Tickers BIIB STOK
< Previous 1 2 3 4 Next >